Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns of survivorship. (March 2019) - Datta, J.; McIntyre, C.A.; Chou, J.; Askan, G.; Drebin, J.A.; Capanu, M.; Balachandran, V.P.; D'Angelica, M.I.; Iacobuzio-Donahue, C.; Basturk, O.; Jarnagin, W.R.; Kingham, T.P.; et al.